Insulet CorporationPODDNASDAQ
Loading
A mid-sized company, with exceptional profitability, showing strong growth priced at a premium.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia.
Comprehensive financial statement data for deep analysis
| Metric | Dec 20 | Dec 21 | Dec 22 | Dec 23 | Dec 24 |
|---|---|---|---|---|---|
| Return on Equity | - | - | - | - | - |
| Return on Invested Capital | - | - | - | - | - |
| Gross Margin | 64.4% | 68.4%↑6.3% | 61.7%↓9.8% | 68.3%↑10.7% | 69.8%↑2.1% |
| Operating Margin | 5.7% | 11.5%↑101.4% | 2.9%↓74.9% | 13.0%↑350.0% | 14.9%↑15.0% |
| Net Margin | 0.8% | 1.5%↑103.3% | 0.4%↓77.0% | 12.2%↑3349.4% | 20.2%↑66.1% |
| Earnings Yield | - | - | - | - | - |